New cell therapy trial targets Hard-to-Treat multiple sclerosis
NCT ID NCT06617793
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This early-stage study tests an experimental cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis whose disease has worsened even while on strong treatments. The goal is to check if YTB323 is safe and can control the disease. Participants receive a single dose, and researchers monitor side effects and disability changes over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
RECRUITINGMontpellier, 34090, France
-
Novartis Investigative Site
RECRUITINGNancy, 54035, France
-
Novartis Investigative Site
RECRUITINGRennes, 35033, France
-
Novartis Investigative Site
RECRUITINGBochum, 44791, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGUlm, 89081, Germany
-
Novartis Investigative Site
RECRUITINGGenova, GE, 16132, Italy
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20132, Italy
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGCórdoba, 14004, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28034, Spain
-
Novartis Investigative Site
RECRUITINGValencia, 46026, Spain
-
Novartis Investigative Site
RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
RECRUITINGLausanne, 1011, Switzerland
-
Novartis Investigative Site
RECRUITINGZurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.